Core Viewpoint - FibroBiologics, Inc. has announced a 1-for-20 reverse stock split to comply with Nasdaq listing requirements and attract broader investor interest, effective March 30, 2026 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from 70,256,883 to approximately 3,512,845 shares [1]. - The reverse stock split was approved by stockholders on February 20, 2026, allowing the Board of Directors to implement it [2]. - No fractional shares will be issued; any resulting fractional shares will be rounded up to the nearest whole share [3]. Group 2: Impact on Shareholders - The reverse stock split will not alter any stockholder's percentage ownership interest in the company, except for adjustments related to fractional shares [3]. - The number of shares available under the company's equity incentive plans and the exercise price of outstanding stock options will be proportionately adjusted [3]. Group 3: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents [5]. - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, and cancer [5].

Core Viewpoint - FibroBiologics, Inc. has successfully closed a registered direct offering of 5,227,275 shares of common stock at $0.33 per share, raising approximately $1.7 million in gross proceeds, with additional potential proceeds from unregistered warrants [1][3]. Group 1: Offering Details - The registered direct offering involved 5,227,275 shares priced at $0.33 each, with concurrent private placement of unregistered warrants for the same number of shares at the same exercise price [1]. - The total gross proceeds from the offering are approximately $1.7 million before deducting fees and expenses, with potential additional proceeds of $1.7 million from the unregistered warrants if fully exercised [3]. - The unregistered warrants will be exercisable upon stockholder approval and will expire five years after such approval [1]. Group 2: Regulatory and Legal Aspects - The shares offered in the registered direct offering were made under a "shelf" registration statement filed with the SEC, which became effective on February 10, 2025 [4]. - The unregistered warrants and shares from the private placement were offered under Section 4(a)(2) of the Securities Act and have not been registered, thus cannot be sold in the U.S. without registration or an exemption [5]. Group 3: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents [9]. - The company aims to advance medical treatments in areas such as wound healing, multiple sclerosis, and cancer through its innovative cell therapy and tissue regeneration approaches [9].